These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31294507)

  • 61. [Analysis of Heterogeneous Biological Characteristics and Prognosis-Related Factors in AL Patients with Mistranslation-Expressed Lymphoid and Myeloid-Related Antigen].
    Ma J; He GM; Liu H; Gao XY; Zhu WJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1263-1268. PubMed ID: 30295236
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
    Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
    Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
    Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases.
    Dunphy CH; Tang W
    Arch Pathol Lab Med; 2007 May; 131(5):748-54. PubMed ID: 17488160
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Immunophenotypes in 115 patients with acute myeloid leukemia by multi-color flow cytometry].
    Wang XB; Yao JX; Zheng JE; Liu J; Li XQ; He YL; Yu JM; Yang J; Wei J; Liu ZP; Huang SA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):250-3. PubMed ID: 15854286
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia.
    Anargyrou K; Paterakis G; Boutsis D; Politou M; Papadhimitriou SI; Siakandaris M; Vassiliadis J; Androulakis A; Meletis J; Rombos J; Tassiopoulou A; Vaiopoulos G
    Eur J Haematol; 2003 Oct; 71(4):294-8. PubMed ID: 12950240
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.
    Wuchter C; Harbott J; Schoch C; Schnittger S; Borkhardt A; Karawajew L; Ratei R; Ruppert V; Haferlach T; Creutzig U; Dörken B; Ludwig WD
    Leukemia; 2000 Jul; 14(7):1232-8. PubMed ID: 10914547
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity.
    Suzuki R; Yamamoto K; Seto M; Kagami Y; Ogura M; Yatabe Y; Suchi T; Kodera Y; Morishima Y; Takahashi T; Saito H; Ueda R; Nakamura S
    Blood; 1997 Sep; 90(6):2417-28. PubMed ID: 9310493
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
    Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
    Salomé B; Gomez-Cadena A; Loyon R; Suffiotti M; Salvestrini V; Wyss T; Vanoni G; Ruan DF; Rossi M; Tozzo A; Tentorio P; Bruni E; Riether C; Jacobsen EM; Jandus P; Conrad C; Hoenig M; Schulz A; Michaud K; Della Porta MG; Salvatore S; Ho PC; Gfeller D; Ochsenbein A; Mavilio D; Curti A; Marcenaro E; Steinle A; Horowitz A; Romero P; Trabanelli S; Jandus C
    Blood Adv; 2019 Nov; 3(22):3674-3687. PubMed ID: 31765481
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients.
    Aref S; Azmy E; El-Bakry K; Ibrahim L; Mabed M
    Hematology; 2018 Jun; 23(5):263-270. PubMed ID: 29161980
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
    Shang L; Chen X; Liu Y; Cai X; Shi Y; Shi L; Li Y; Song Z; Zheng B; Sun W; Ru K; Mi Y; Wang J; Wang H
    Int J Lab Hematol; 2019 Feb; 41(1):23-31. PubMed ID: 30264491
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
    Iriyama N; Hatta Y; Takeuchi J; Ogawa Y; Ohtake S; Sakura T; Mitani K; Ishida F; Takahashi M; Maeda T; Izumi T; Sakamaki H; Miyawaki S; Honda S; Miyazaki Y; Taki T; Taniwaki M; Naoe T
    Leuk Res; 2013 Sep; 37(9):1021-6. PubMed ID: 23810283
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
    Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
    De J; Zanjani R; Hibbard M; Davis BH
    Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
    Eckel AM; Cherian S; Miller V; Soma L
    Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
    Klobusicka M; Kusenda J; Babusikova O
    Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
    Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
    Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.
    Masetti R; Bertuccio SN; Pession A; Locatelli F
    Br J Haematol; 2019 Feb; 184(3):337-347. PubMed ID: 30592296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.